Loading stock data…
NGVT
$69.04+2.11 (+3.15%)
Market ClosedLast close Jun 9
Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ingevity Corporation in the Basic Materials sector is trading at $69.04 with a market capitalization of $2.3B. Wall Street consensus targets $85.50 (4 analysts), implying a +23.8% move over the next 12 months. The stock is currently 13% below its 52-week high of $79.29, remaining 9.3% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +23.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$69.04
Potential Downside
0%
Whystock Fair Value$69.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments:...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.33B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-328.53%
Volume
Today's trading volume
128,007
Recent News
Why Is Ingevity (NGVT) Down 10.8% Since Last Earnings Report?
Ingevity (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ingevity (NGVT) Q1 2026 Earnings Transcript
David Li: Thank you, Mickey, and good morning, everyone. Starting with our strategic portfolio transformation, we were pleased to complete the sale of the Ozark Materials, Road Markings product line, on April 15 to PPG in an all-cash transaction valued at approximately $65 million. This follows the divestiture announced in January of our North Charleston CTO refinery and a majority of the Industrial Specialties product line for approximately $93 million of net proceeds.
Ingevity Q1 Earnings Call Highlights
Ingevity (NYSE:NGVT) reported higher first-quarter 2026 sales and reaffirmed its full-year outlook as management highlighted progress on portfolio simplification, strong margins in its Performance Materials business and continued share repurchases. On the company’s earnings call, President and CEO
NGVT Q1 Earnings Top Estimates on Pricing and FX Tailwinds
Ingevity beats Q1 estimates as pricing actions and FX gains lift sales and earnings, despite weakness in Road Markings and lower asset utilization.
The Bull Case For Ingevity (NGVT) Could Change Following Q1 2026 Results And Portfolio Reshaping Steps
In the past week, Ingevity Corporation reported first-quarter 2026 results with sales of US$258.0 million and net income of US$59.8 million, while advancing portfolio reshaping through divestitures and reaffirming full-year guidance. At the same time, shareholders expanded the 2025 Omnibus Incentive Plan by 580,000 shares and approved ESOP-related shelf registration, highlighting an emphasis on equity-based compensation and employee ownership alongside a tighter focus on higher-margin...